Prognostic Factors and Role of Allo-HSCT in First Salvage Therapy for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Blinatumomab and Inotuzumab Ozogamicin
Posted inHematology-Oncology news Oncology

Prognostic Factors and Role of Allo-HSCT in First Salvage Therapy for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Blinatumomab and Inotuzumab Ozogamicin

Early measurable residual disease (MRD) negativity and timing of relapse are crucial for risk stratification in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with blinatumomab and/or inotuzumab ozogamicin. Allogeneic stem cell transplantation (allo-HSCT) benefits select high-risk patients.
Secondary Autoimmune and Inflammatory Diseases Post-Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, and Clinical Outcomes from the EBMT Registry
Posted inAllergy & Immunology Hematology-Oncology news

Secondary Autoimmune and Inflammatory Diseases Post-Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, and Clinical Outcomes from the EBMT Registry

This retrospective EBMT study identifies secondary autoimmune and inflammatory diseases as rare but significant complications following allo-HSCT, highlighting their incidence, risk factors, and impact on patient survival, calling for improved diagnostic and management strategies.
Fecal Calprotectin as a Biomarker for Diagnosis and Monitoring of Gastrointestinal Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation
Posted inClinical Updates Gastroenterology Hematology-Oncology news

Fecal Calprotectin as a Biomarker for Diagnosis and Monitoring of Gastrointestinal Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

Fecal calprotectin offers a non-invasive, dynamic biomarker to predict, diagnose, and monitor GI-GVHD post-allo-HSCT, correlating with endoscopic severity and treatment response, but requires integrated clinical interpretation due to limited specificity.
Tuberculosis Post-Allogeneic Hematopoietic Stem Cell Transplantation: Insights from a Decade-Long Nationwide Study in a Low-Incidence Setting
Posted inClinical Updates Hematology-Oncology Infectious Diseases news

Tuberculosis Post-Allogeneic Hematopoietic Stem Cell Transplantation: Insights from a Decade-Long Nationwide Study in a Low-Incidence Setting

This nationwide retrospective study in France highlights the rare but severe incidence of tuberculosis (TB) in Allo-HSCT recipients, identifying birth in high-prevalence countries as a primary risk factor and emphasizing the need for targeted latent TB screening.